Jpmorgan Chase & CO Macrogenics Inc Transaction History

Jpmorgan Chase & CO

$1.23 Trillion
Q4 2024

A detailed history of Jpmorgan Chase & CO transactions in Macrogenics Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 546,807 shares of MGNX stock, worth $1.54 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

546,807

Previous 324,902 68.3%

Holding current value

$1.54 Million

Previous $1.07 Million 66.39%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$3.18 - $4.46 $705,657 - $989,696	221,905 Added 68.3%	546,807 $1.78 Million
Q3 2024 Dec 26, 2024	SELL	$3.0 - $5.55 $466,077 - $862,242	-155,359 Reduced 32.35%	324,902 $1.07 Million
Q3 2024 Nov 08, 2024	SELL	$3.0 - $5.55 $466,077 - $862,242	-155,359 Reduced 32.35%	324,902 $1.07 Million
Q2 2024 Dec 26, 2024	BUY	$3.31 - $18.51 $514,238 - $2.88 Million	155,359 Added 47.82%	480,261 $2.04 Million
Q2 2024 Aug 12, 2024	SELL	$3.31 - $18.51 $1.82 Million - $10.2 Million	-548,788 Reduced 53.33%	480,261 $2.04 Million
Q1 2024 Dec 26, 2024	BUY	$9.77 - $21.47 $6.88 Million - $15.1 Million	704,147 Added 216.73%	1,029,049 $15.1 Million
Q1 2024 May 10, 2024	SELL	$9.77 - $21.47 $1.03 Million - $2.27 Million	-105,695 Reduced 9.31%	1,029,049 $15.1 Million
Q4 2023 Dec 26, 2024	BUY	$4.48 - $10.11 $3.63 Million - $8.19 Million	809,842 Added 249.26%	1,134,744 $10.9 Million
Q4 2023 Feb 12, 2024	BUY	$4.48 - $10.11 $377,099 - $850,999	84,174 Added 8.01%	1,134,744 $10.9 Million
Q3 2023 Nov 14, 2023	SELL	$4.48 - $6.19 $893,410 - $1.23 Million	-199,422 Reduced 15.95%	1,050,570 $4.9 Million
Q2 2023 Aug 11, 2023	BUY	$4.62 - $7.54 $4.84 Million - $7.9 Million	1,047,650 Added 517.76%	1,249,992 $6.69 Million
Q1 2023 May 18, 2023	BUY	$4.82 - $7.24 $222,577 - $334,328	46,178 Added 29.57%	202,342 $1.45 Million
Q1 2023 May 11, 2023	SELL	$4.82 - $7.24 $385,277 - $578,714	-79,933 Reduced 33.86%	156,164 $1.12 Million
Q4 2022 Feb 13, 2023	SELL	$3.34 - $6.98 $311,819 - $651,645	-93,359 Reduced 28.34%	236,097 $1.58 Million
Q3 2022 Nov 14, 2022	SELL	$3.01 - $5.22 $209,489 - $363,301	-69,598 Reduced 17.44%	329,456 $1.14 Million
Q2 2022 Aug 11, 2022	BUY	$2.25 - $9.99 $259,411 - $1.15 Million	115,294 Added 40.63%	399,054 $1.18 Million
Q1 2022 May 11, 2022	BUY	$8.12 - $16.9 $1.52 Million - $3.17 Million	187,724 Added 195.47%	283,760 $2.5 Million
Q4 2021 Feb 10, 2022	SELL	$15.91 - $21.88 $74,633 - $102,639	-4,691 Reduced 4.66%	96,036 $1.54 Million
Q3 2021 Nov 12, 2021	BUY	$19.74 - $28.7 $1.99 Million - $2.89 Million	100,727 New	100,727 $2.11 Million

Others Institutions Holding MGNX

# of Institutions

131

Shares Held

56M

Call Options Held

28.3K

Put Options Held

197K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $173M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Macrogenics Inc Transaction History